Overview

Inflammatix’s initial products – the HostDx™ Fever and HostDx™ Sepsis tests – read a patient's immune system to overcome the current challenges in diagnosing acute infections and sepsis. The tests will target a collective market of an estimated 100 million patient visits each year in the United States alone.\(^1\)\(^-\)\(^4\)

Bacterial and viral infections are difficult to diagnose and current testing methods, which look for specific pathogens or nonspecific biomarkers, are inaccurate or too slow.\(^5\)\(^,\)\(^6\) Determining when an infection progresses to sepsis, a life-threatening condition, is an imprecise and challenging process. These diagnostic challenges result in delayed or incorrect treatment, which harms patients and furthers the growing and costly global problems of antibiotic resistance and sepsis.

Our data-driven technology works by measuring the expression levels of multiple host immune genes. We then apply proprietary algorithms to produce clinically actionable results in patients with suspected infection and/or sepsis. This approach will enable physicians to quickly get the right treatments to the right patients, resulting in improved outcomes and reduced health system costs. Our tests, run on a standard blood draw, will be FDA-cleared and performed on sample-to-answer, PCR-based devices that are utilized at or near the point of care in clinics and hospitals. We plan to bring our HostDx tests to market ourselves and license our technology to diagnostic instrument partners.

<table>
<thead>
<tr>
<th>HostDx™ FEVER</th>
<th>HostDx™ SEPSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Questions Answered</strong></td>
<td><strong>HostDx™ SEPSIS</strong></td>
</tr>
<tr>
<td>✔ Is the suspected infection bacterial or viral?</td>
<td>✔ Is a bacterial infection present?</td>
</tr>
<tr>
<td>✔ Is a viral infection present?</td>
<td>✔ Is the patient likely to have or develop sepsis?</td>
</tr>
<tr>
<td>✔ Whether or not the patient needs antibiotics</td>
<td>✔ Whether or not the patient needs antibiotics</td>
</tr>
<tr>
<td><strong>Intended Clinical Settings</strong></td>
<td><strong>HostDx™ SEPSIS</strong></td>
</tr>
<tr>
<td>✔ Outpatient settings, including primary care and pediatric offices</td>
<td>✔ Emergency departments</td>
</tr>
<tr>
<td>✔ Urgent care and walk-in clinics</td>
<td>✔ Intensive care and neonatal units, hospital wards</td>
</tr>
<tr>
<td><strong>Target Patients</strong></td>
<td><strong>HostDx™ SEPSIS</strong></td>
</tr>
<tr>
<td>✔ Those with suspected infection</td>
<td>✔ Those with suspected infection</td>
</tr>
<tr>
<td>✔ Patients assessed for sepsis in the Emergency Room, ICU or hospital ward</td>
<td></td>
</tr>
<tr>
<td><strong>Turnaround Time</strong></td>
<td><strong>HostDx™ SEPSIS</strong></td>
</tr>
<tr>
<td>✔ &lt;30 minutes</td>
<td>✔ &lt;30 minutes</td>
</tr>
</tbody>
</table>
The Diagnostic Challenge

Acute Infections

Bacterial and viral infections are diverse and challenging to diagnose. Bacterial infections need to be treated with antibiotics quickly in order to prevent disease progression including sepsis. Current “find the pathogen” testing approaches are limited because most infections never enter the bloodstream. Blood culture, for example, is the “gold standard” for diagnosing infections, but misses at least 70% of bacterial infections, as the majority of infections do not enter the bloodstream. Current testing approaches are also too slow (e.g., culture takes >24 hours). As a result, infections are often blindly – and incorrectly – treated with antibiotics. This practice can cause direct harm through antibiotic side effects, and also contributes to antibiotic resistance and increases costs. Conversely, bacterial infections, which require antibiotics, are sometimes missed.

Sepsis

Sepsis is a fast-progressing and life-threatening condition in which the body’s immune system, already fighting a severe infection, becomes dysregulated and damages its own tissues and organs. Sepsis is a medical emergency that requires rapid administration of antibiotics and fluids. Data show that risk of death from sepsis increases by 7.6% with every hour of delay in beginning treatment.

There is currently no single, definitive test for sepsis; rather, physicians typically rely on a battery of tests and clinical criteria – all with sub-optimal performance. As a result, sepsis diagnoses are often delayed or missed, with potentially deadly consequences, while other patients without sepsis may be overtreated.

Sepsis: A Deeper Look

Sepsis is not a specific illness, but rather a syndrome whose underlying cause and processes are not well-understood. According to recently updated clinical guidelines, a sepsis diagnosis requires two factors: 1) presence of an infection; and 2) an increase of two or more points in a patient’s Sequential Organ Failure Assessment (SOFA) score – a formula used to quantify illness severity. SOFA assigns points to a number of factors to collectively measure organ dysfunction and risk of mortality. A higher SOFA score is associated with an increased risk of death. A newer, abbreviated version, termed qSOFA (for quick SOFA), is also used.
to provide simple criteria to identify patients with suspected infection who are likely to have poor outcomes.\textsuperscript{12}

Inflammatix’s HostDx Sepsis test is uniquely designed to determine both factors in sepsis diagnosis: whether an infection is present and the severity of infection (i.e., degree of dysregulated immune system response). Data suggest that the test is more accurate than SOFA in identifying patients likely to have or develop sepsis (based on risk-of-mortality measurements).\textsuperscript{16}

**HostDx Test Development and Validation**

Our HostDx tests are being developed using advanced bioinformatics that integrate multiple clinical cohorts, representing a broad spectrum of disease. Our scientific approach has been validated in 38 retrospective cohorts (N=2,452) and 6 prospective cohorts (N=1,833) are enrolled. Results have been published in leading peer-reviewed journals such as *Science Translational Medicine* and *Nature Communications*.\textsuperscript{16–18} This heterogeneity of patient data provides confidence that HostDx test results are accurate and generalizable – regardless of infection type, patient population and setting.

**HostDx FEVER**

* bacterial infection is the “case”; viral infection is the “control”

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
**Indication** & **Sensitivity** & **Specificity** \\
\hline
Bacterial Infection* & 94\% & 76\% \\
\hline
\end{tabular}
\end{table}

**HostDx Sepsis** – This test helps determine whether a suspected infection is likely bacterial or viral. In a pooled analysis of 1,040 patient samples from 24 validation study cohorts of patients with a suspected infection, the test demonstrated high accuracy in distinguishing between bacterial and viral infections (Figure 1).\textsuperscript{16} The test’s performance was consistent regardless of the subtype of infection in the study cohort, which is important because infection types fluctuate in different clinical settings and times of year (e.g., viral infection rates increase during flu season).

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|}
\hline
**Infection Type** & **Estimated Prevalence** & **NPV** & **PPV** & **Estimated Prevalence** & **NPV** & **PPV** \\
\hline
Bacterial Infection & 35\% Bacterial / 65\% Viral & 97\% & 69\% & 20\% Bacterial / 80\% Viral & 99\% & 50\% \\
\hline
\end{tabular}
\end{table}

Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.
### HostDx SEPSIS

**Figure 2**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Infection</td>
<td>94%</td>
<td>60%</td>
</tr>
<tr>
<td>Viral Infection</td>
<td>53%</td>
<td>91%</td>
</tr>
<tr>
<td>30-day mortality (sepsis)</td>
<td>95%</td>
<td>64%</td>
</tr>
</tbody>
</table>

**HostDx Sepsis Test** – This test helps diagnose sepsis by detecting the presence of a bacterial and/or viral infection and its severity. The test’s ability to identify infections was validated in 20 cohorts of 1,057 patients.\(^7\) The test’s performance was demonstrated in five cohorts of 189 patients diagnosed with sepsis at the time of hospital admission and four cohorts of 282 patients with hospital-acquired sepsis.\(^8\) See Figure 2 for performance summary of the HostDx Sepsis test.

Inflammatix continues to conduct clinical studies to demonstrate the performance of its HostDx tests in a variety of clinical settings.

### Regulatory Clearance and Commercialization

Inflammatix plans to bring its HostDx tests to market and to also license its technology to diagnostic instrument partners to functionalize on their platforms. This approach will allow us to rapidly grow the clinical evidence base and provide broad patient access for the tests. We will validate and obtain regulatory approval for each test and launch the tests to clinics and hospitals in the United States and globally. Once cleared, interventional clinical utility studies will be conducted to demonstrate that with HostDx tests, physicians can better diagnose (and confidently rule out) acute infections and sepsis—thus improving patient care and lowering healthcare costs.

### REFERENCES: